ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0772

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis

Andreas Kerschbaumer1, Marlene Steiner2, Suzanne D. Khalili1, Daniel Aletaha3 and Josef Smolen4, 1Medical University of Vienna, Vienna, Wien, Austria, 2Medical University Vienna, Vienna, Wien, Austria, 3Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, 4Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2024

Keywords: Access to care, American College of Rheumatology Criteria, Outcome measures, Psoriatic arthritis, socioeconomic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Plenary I

Session Type: Plenary Session

Session Time: 9:15AM-10:45AM

Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent of biological disease modifying anti-rheumatic drugs (DMARD), double-blind randomized controlled trials (RCT) have been the mainstay of drug development. In rheumatoid arthritis clinical trials, over time, a significant increase in placebo response (PBO) rates has been observed, and it is unclear whether this likewise applies to PsA clinical trials. We also hypothesized that one element contributing to increasing placebo responses are changing recruitment patterns with an increasing move towards geographic areas with less affluent health care systems.

Methods: We analysed the placebo arms of all available trials with reports on ACR response rates at week 12. To ensure completeness of trial acquisition, we identified all placebo controlled RCTs investigating biological or targeted synthetic DMARDs in PsA patients with established csDMARD background therapy until December 19th, 2023. First, we quantified the association of ACR20 PBO rates with the study start year. Next, to assess geographic distribution, we extracted the numbers of recruiting centres per country from the original articles or from clinicaltrials.gov. We then used world bank data on the per capita gross national income (GNI) of each recruiting country to calculate a weighted GNI per study and performed linear mixed model regression with a random effect on study level, weighted by the number of patients per study, and adjusted for the global trend of rising GNPs over time. Statistics were conducted using R (version 4.3.1).

Results: For complete trial evaluation, two independent researchers screened in total 2.389 articles, of which 154 were assessed in detail, with 51 reports finally fulfilling the criteria for trial analysis. Of the included studies the year of study start ranged from 1996 to 2019. A significant positive association of PBO with the study start year was found (estimate: 0.92±0.16;p< 0.001). Recruitment areas have expanded from initially covering only North America to an increasing global recruitment over time (Figure 1), with more recent studies being conducted in less affluent countries. We identified a strong and significant negative association of the weighted and normalised GNP per study and PBO rates in a study, with an estimate of an ACR20 response -5.22%±1.13 per 10.000 international Dollars (p< 0.001;Figure 2).

Conclusion: PBO rates are rising over time, in parallel to the change of geographic recruiting patterns, with more recent RCTs recruiting increasingly in less affluent countries. Our data support the hypothesis that geographic recruitment changes are a significant contributor to the higher placebo rates observed in more recent clinical trials. One explanation may be the more limited access to health care and innovative therapies in less affluent countries, leading to preference for inclusion in clinical trials and subsequently also higher regression to the mean, which manifests as placebo response. These effects should have implications for sponsors, investigators, patients, health care providers and political stakeholders.

Supporting image 1

Figure 1. Patterns of recruiting centers (per country) from 1996 to 2019 (study start).

Supporting image 2

Figure 2. Association of American College of Rheumatology 20% response rates with the study start (year) per study in placebo arms of PsA clinical trials. The size of the bubbles represents the number of patients in each placebo arm analyzed.

Supporting image 3

Figure 3. Association of American College of Rheumatology 20% response rates with the weighted gross national income (GNI) per study in placebo arms of PsA clinical trials. The size of the bubbles represents the number of patients in each placebo arm analyzed.


Disclosures: A. Kerschbaumer: AbbVie, 2, Böhringer-Ingelheim, 12, Conference attendance, Galapagos, 6, Janssen, 1, 2, 6, Lilly, 2, 12, Travel/Conference attendance, MSD, 6, Novartis, 6, Pfizer, 6, UCB, 2; M. Steiner: None; S. Khalili: None; D. Aletaha: AbbVie, 2, 5, 6, Galapagos, 2, 5, 6, Gilead, 2, 5, 6, Janssen, 2, 5, 6, Lilly, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6; J. Smolen: Abbvie, 5, 6, Amgen, 6, Astra-Zeneca, 5, 6, Astro, 6, Bristol-Myers Squibb, 6, Celgene, 6, Celltrion, 6, Chugai, 6, Eli Lilly, 5, 6, Gilead, 6, ILTOO, 6, Janssen, 6, Merck Sharp & Dohme, 6, Novartis, 5, 6, Pfizer, 6, Roche, 5, 6, R-Pharma, 6, Samsung, 6, Sanofi, 6, UCB Pharma, 6.

To cite this abstract in AMA style:

Kerschbaumer A, Steiner M, Khalili S, Aletaha D, Smolen J. Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/global-recruiting-patterns-are-associated-with-placebo-response-rates-in-clinical-trials-of-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/global-recruiting-patterns-are-associated-with-placebo-response-rates-in-clinical-trials-of-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology